Filing Flows › Pulmonx (LUNG) › Recalls, complaints & regulation
Pulmonx (LUNG): recalls and clinical trials
Pulmonx (LUNG) beyond its filings: 0 recalls in the last 12 months (1 in five years, 0 Class I); 3 active clinical trials.
Latest recalls
- 2023-11-15 · FDA device · Zephyr Endobronchial Valve (EBV) 5.5-LP, REF: EBV-TS-5.5-LP
Pulmonx's latest quarter
Pulmonx, Q3 2026: revenue $22.8M (+6% year over year), operating margin -32.8%, net loss $8.4M, operating cash flow −$3.2M. The chart follows the revenue to costs, profit and cash.
Questions
Has Pulmonx had any recalls?
1 recall on file over five years from the FDA, CPSC and NHTSA; 0 in the last 12 months.
How many clinical trials does Pulmonx have?
3 active studies on ClinicalTrials.gov, 0 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.